Allwin Medical Devices, Inc. appears in FDA's 510(k) database as the applicant for The D-Tip Denudation Pipette, cleared substantially equivalent on October 9, 2026. The submission was received April 15, 2026, and reviewed under product code MQH, regulation 884.6130, in the Obstetrics/Gynecology panel. The filing address of record is in Anaheim, California, with Digish Mehta listed as contact. That address is a filing detail, not a verified corporate headquarters. [1][2][7]
The cleared device and its regulatory classification
K261234 covers The D-Tip Denudation Pipette, classified as a class II Microtools, Assisted Reproduction (Pipettes) device under 21 CFR 884.6130. FDA records a Traditional 510(k), not third-party reviewed, with a Statement rather than a summary, and no authorized Predetermined Change Control Plan. The decision description is Substantially Equivalent. [1][2][7]
Independent indexes of the same FDA record repeat the applicant name, product code MQH, decision date of October 9, 2026, and Obstetrics/Gynecology review panel, giving a consistent picture of the clearance across public databases. [7][8]
What the company says about the product line
Allwin's own site describes denuding pipettes for IVF as micropipettes designed for the manipulation and transfer of oocytes and embryos, offered in a range of tip sizes for clinical and research labs, with unbreakable plastic tips intended not to scratch dishes and a stated focus on minimizing the risk of oocyte degeneration. These are the company's characterizations, not independently verified performance claims. [5]
The company's Denudation Pipettes category page lists a single result, D-TIP Denudation Pipettes, and the wider Women's Health category shows 41 results across paginated listings, including AspiPump 90D and a silicone hysterosalpingography catheter. The site notes that not all displayed products may be available or approved in every region. [3][6]
Applicant identity and corporate footprint
The FDA record names Allwin Medical Devices, Inc. as applicant, with a contact in Anaheim, California. Company pages carry an Indian corporate identity number, U33110MH2002PTC137069, and a grievance contact, and describe manufacturing at a facility in India. The relationship between the U.S. applicant entity and that Indian corporate identity is not established by these sources. [1][3][4]
Company pages also list a Berlin, Germany address and a placeholder-style contact block, while stating that products may not be approved in every region. No parent, ownership structure, or verified headquarters is documented in the public information. [4][6]
Portfolio context and limits of the record
The supplied collection contains one linked 510(k) record, K261234, with a single SESE decision; the sample of records mirrors that count. This is an as-of snapshot of supplied filings, not a statement of total company sales, total portfolio, or safety performance. No recall records appear in the supplied sample. [1]
FDA.report's related-records list places K261234 alongside other denudation and micromanipulation pipette clearances from different applicants, which indicates the product category's regulatory history without implying any relationship between those firms and Allwin. [7]

